Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Doxorubicin Impairs Crossbridge Turnover Kinetics in Skinned Cardiac Trabeculae after Acute and Chronic Treatment

Evert L. de Beer, Antonio E. Bottone, Jolanda van der Velden and Emile E. Voest
Molecular Pharmacology June 2000, 57 (6) 1152-1157;
Evert L. de Beer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio E. Bottone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jolanda van der Velden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emile E. Voest
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Crossbridge dynamics underlying the acute and chronic inotropic effects of doxorubicin (Dox) were studied by application of releasing length steps (amplitude, 0.5–10%) to skinned cardiac trabeculae. Acute incubation of trabeculae with 20 μM Dox for 30 min resulted in a decrease of the velocity of unloaded shortening (V0, from 9.3 ± 1.1 to 7.7 ± 0.7 μm/s, P < .05) and in an increase of the rate of force redevelopment (τr, from 56 ± 4 to 65 ± 3 ms,P < .05) in response to step amplitudes ranging from 5 to 10%. In contrast, chronic Dox treatment in rats (2 mg/kg/week for 4 weeks) significantly impaired trabecular crossbridge dynamics after step releases of 0.5%. This was reflected by an increase of all time constants describing tension recovery: τ1, from 10 ± 1 to 14 ± 1 ms; τ2, from 65 ± 6 to 82 ± 6 ms; τ3, from 92 ± 7 to 293 ± 67 ms;P < .05. In addition, V0 was decreased (from 8.6 ± 0.6 to 6.8 ± 0.3 μm/s, P< .05) and τr was increased (from 67 ± 4 to 89 ± 3 ms; P < .05) in the slack-test. We found that chronic Dox treatment resulted in a shift from the “high ATPase” α-myosin heavy chain (MHC) isoform toward the “low-ATPase” β-MHC isoform in the ventricles (control: α-MHC 79 ± 2% and β-MHC 21 ± 2%; Dox-treated: α-MHC 53 ± 2% and β-MHC 47 ± 2%; P < .05). The present results show that acute Dox incubation affects the detachment rate of crossbridges, which leads to a delayed relaxation and an arrest of crossbridges in strongly bound states. In contrast, chronic Dox treatment leads to an impairment of both the attachment and detachment rates in the crossbridge cycle, which may be explained by an altered MHC isoform composition in ventricular myocardium. Interfering with Dox-induced alterations of crossbridge kinetics may provide a new strategy to prevent Dox-associated cardiotoxicity.

Footnotes

  • Send reprint requests to: Dr. E. L. de Beer, Department of Medical Physiology and Sports Medicine, Utrecht University, P.O. Box 80043, 3508 TA Utrecht, the Netherlands. E-mail:e.l.debeer{at}med.uu.nl

  • This research was supported by Grant 93.074 from the Netherlands Heart Foundation.

  • Abbreviations:
    Dox
    doxorubicin
    MHC
    myosin heavy chain
    • Received November 4, 1999.
    • Accepted February 1, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 57 (6)
Molecular Pharmacology
Vol. 57, Issue 6
1 Jun 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Doxorubicin Impairs Crossbridge Turnover Kinetics in Skinned Cardiac Trabeculae after Acute and Chronic Treatment
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Doxorubicin Impairs Crossbridge Turnover Kinetics in Skinned Cardiac Trabeculae after Acute and Chronic Treatment

Evert L. de Beer, Antonio E. Bottone, Jolanda van der Velden and Emile E. Voest
Molecular Pharmacology June 1, 2000, 57 (6) 1152-1157;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Doxorubicin Impairs Crossbridge Turnover Kinetics in Skinned Cardiac Trabeculae after Acute and Chronic Treatment

Evert L. de Beer, Antonio E. Bottone, Jolanda van der Velden and Emile E. Voest
Molecular Pharmacology June 1, 2000, 57 (6) 1152-1157;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Therapeutic Effects of FGF23 Antagonists in Hyp Mice
  • TRPV3 and TRPV4 Channels Coassemble into Heterotetramers
  • Secretin Amino-Terminal Structure-Activity Relationships and Complementary Mutagenesis at the Site of Docking to the Secretin Receptor
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics